Anti-interleukin-1 therapy in the management of gout. - Wikidata - awgldk - TriplyDB

Anti-interleukin-1 therapy in the management of gout.

Anti-interleukin-1 therapy in the management of gout.

http://www.wikidata.org/entity/Q38177186

about

Gout increases risk of fracture: A nationwide population-based cohort study.Association analysis between genetic variants in interleukin genes among different populations with hyperuricemia in Xinjiang Autonomous Region Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice.Pharmacokinetics considerations for gout treatments.Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review.How neutrophil extracellular traps orchestrate the local immune response in gout.Management of Gout and Hyperuricemia in CKD.The burgeoning field of innate immune-mediated disease and autoinflammation.The inflammasome as a target for pain therapy.The safety of treatment options available for gout.Gouty arthritis of the spine in a renal transplant patient: a clinical case report: an unusual presentation of a common disorder.The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents.Anakinra in resistant gout: a case report.Inflammasomes in livestock and wildlife: Insights into the intersection of pathogens and natural host species NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis

P2860

Q33590612-A5007024-30C0-466C-9A1D-14D22A21B72B Q36375514-7857FCC7-2A38-421D-B503-E92798C6941B Q36546979-A72E7DAE-8F6D-4F40-AFF8-C25C438800F9 Q38210284-C9849737-702F-4734-9CAE-9BA29F95CCB1 Q38263540-45278981-F34E-4EDF-8F5B-2A3F824547FA Q38498741-B9D6D169-ABA2-424A-BC7C-DD74D45B0BF1 Q38812962-79690D38-9387-4B1C-98C2-E13E9043C698 Q38967233-7BC764AA-E23A-428F-AA23-8B0A916BB231 Q39036848-B84A5FD4-6318-426F-9E24-F6E7D944AE71 Q39092018-6190B18E-B180-4624-9683-6EB07B4C9BD1 Q40162428-507A29F4-8A3D-422E-B52C-91CA80263D29 Q47796204-6AA654FF-3B0D-42C4-83CC-393F0EFAC188 Q47986832-E5762EE1-814D-4A62-A8B2-3E7C97EF75E4 Q57179097-AB2B85FC-90D9-4526-A935-C0297EB5AC1C Q58801340-9F1AD878-8458-4D32-89D4-65D10D52A57E

P2860

Anti-interleukin-1 therapy in the management of gout.

http://www.wikidata.org/entity/Q38177186

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Anti-interleukin-1 therapy in the management of gout.

@en

type

label

Anti-interleukin-1 therapy in the management of gout.

@en

prefLabel

Anti-interleukin-1 therapy in the management of gout.

@en

P1433

Q38177186-B7474B19-5AEF-4A5B-B7B0-654306223B7D

P1476

Q38177186-14570C70-3900-4D49-BDB4-CCAB29762337

P2093

Q38177186-CC8453A7-2627-4040-AA2E-974D4E605C63

P2860

Q38177186-00EBF934-8F18-4EB6-AE05-6AB83EEA0527

Q38177186-0D034865-DCD1-4BE1-AE4F-FB5F0D1041B4

Q38177186-0F8E20D7-C6E8-4C59-AC6B-BDFFA6708C61

Q38177186-1169556F-A5D3-44F1-9F63-435B2016F9BE

Q38177186-190212E2-2113-4BC1-BECA-DCB3840DDF8C

Q38177186-31337C2E-EAFA-4064-B9EF-76478FAD02CA

Q38177186-39635CE7-82B8-43A3-B810-A3259E431D15

Q38177186-6D6661DE-6708-4DA8-8C77-298B33D36BE4

Q38177186-8CB2A3DC-15AE-4D71-B9A7-89B4010C8E66

Q38177186-A37AB9D3-A0E4-44B9-9E22-68C14068EDC4

P2888

Q38177186-BB2365CB-FF56-47B4-9C3A-940A176C59A2

P304

Q38177186-F8A7FAB1-8731-4C64-B431-D9063E9ED2C0

P31

Q38177186-A88D42ED-79D5-40E4-8A9A-5B26247DBFB5

P356

Q38177186-BE2B7DC5-C04A-446F-99DA-2766318EBD29

P433

Q38177186-46BAB5D7-87D1-424E-8CFE-FFEF92611DCA

P478

Q38177186-B73B7B02-6ECC-489D-9368-A3457A3FA4E7

P577

Q38177186-67F39343-A521-4823-9FDC-17181B2B87F5

P6179

Q38177186-623D2A42-D8EC-4EF7-B435-C0F73C24476B

P698

Q38177186-1103514F-BEFC-40F8-92AA-A4655380057E

P356

S11926-013-0398-Z

P1433

Current Rheumatology Reports

P1476

Anti-interleukin-1 therapy in the management of gout.

@en

P2093

Naomi Schlesinger

http://www.w3.org/2001/XMLSchema#string

P2860

A pilot study of IL-1 inhibition by anakinra in acute gout

Gout-associated uric acid crystals activate the NALP3 inflammasome

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

The inflammatory process of gout and its treatment

MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.

P2888

s11926-013-0398-z

P304

398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-013-0398-Z

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015608796

http://www.w3.org/2001/XMLSchema#string

P698

24407823

http://www.w3.org/2001/XMLSchema#string